Bio­haven con­tin­ues push for oral mi­graine med Nurtec amid new port­fo­lio line up

Bio­haven is spend­ing to move the oral mi­graine drug mar­ket — and it seems to be work­ing. The bio­phar­ma re­port­ed $463 mil­lion in Nurtec sales for 2021, with $190 mil­lion of that in the fourth quar­ter alone, it re­port­ed dur­ing an earn­ings call Fri­day.

Dri­ving that growth? SG&A ex­pens­es of $189 mil­lion in the fourth quar­ter, an in­crease of 66% over the same pe­ri­od in the pre­vi­ous year. SG&A or sell­ing, gen­er­al and ad­min­is­tra­tive costs in­clude every­day op­er­at­ing ex­pens­es that in­clude things salaries and mar­ket­ing and ad­ver­tis­ing ex­pens­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER